Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Given Consensus Recommendation of “Moderate Buy” by Analysts

Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) have received an average rating of “Moderate Buy” from the twenty-five ratings firms that are covering the firm, MarketBeat reports. One investment analyst has rated the stock with a sell rating, five have issued a hold rating and nineteen have given a buy rating to the company. The average 12-month price objective among brokers that have issued ratings on the stock in the last year is $298.61.

A number of research firms have recently weighed in on ALNY. Needham & Company LLC reissued a “buy” rating and set a $320.00 price target on shares of Alnylam Pharmaceuticals in a research report on Monday, January 13th. Scotiabank raised their price objective on shares of Alnylam Pharmaceuticals from $305.00 to $310.00 and gave the stock a “sector outperform” rating in a report on Friday, November 1st. Wolfe Research lowered shares of Alnylam Pharmaceuticals from a “peer perform” rating to an “underperform” rating in a research note on Tuesday, November 12th. Canaccord Genuity Group lifted their price target on Alnylam Pharmaceuticals from $366.00 to $384.00 and gave the stock a “buy” rating in a research note on Friday, November 1st. Finally, Bank of America boosted their price objective on Alnylam Pharmaceuticals from $307.00 to $314.00 and gave the company a “buy” rating in a report on Monday, October 14th.

Insider Activity

In related news, CEO Yvonne Greenstreet sold 5,219 shares of Alnylam Pharmaceuticals stock in a transaction dated Tuesday, November 26th. The shares were sold at an average price of $250.98, for a total transaction of $1,309,864.62. Following the sale, the chief executive officer now directly owns 78,880 shares in the company, valued at $19,797,302.40. The trade was a 6.21 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CMO Pushkal Garg sold 52,592 shares of the company’s stock in a transaction dated Monday, January 27th. The stock was sold at an average price of $285.00, for a total transaction of $14,988,720.00. Following the completion of the sale, the chief marketing officer now directly owns 11,989 shares of the company’s stock, valued at $3,416,865. The trade was a 81.44 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 73,964 shares of company stock valued at $20,622,925. Insiders own 1.50% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in ALNY. Huntington National Bank boosted its stake in Alnylam Pharmaceuticals by 91.8% during the 3rd quarter. Huntington National Bank now owns 94 shares of the biopharmaceutical company’s stock valued at $26,000 after purchasing an additional 45 shares in the last quarter. Hollencrest Capital Management acquired a new stake in shares of Alnylam Pharmaceuticals in the third quarter valued at $29,000. R Squared Ltd bought a new position in Alnylam Pharmaceuticals during the fourth quarter valued at about $33,000. Washington Trust Advisors Inc. acquired a new position in Alnylam Pharmaceuticals during the third quarter worth about $42,000. Finally, True Wealth Design LLC raised its position in Alnylam Pharmaceuticals by 15,300.0% in the third quarter. True Wealth Design LLC now owns 154 shares of the biopharmaceutical company’s stock worth $42,000 after acquiring an additional 153 shares in the last quarter. Institutional investors and hedge funds own 92.97% of the company’s stock.

Alnylam Pharmaceuticals Price Performance

Shares of NASDAQ ALNY opened at $276.31 on Thursday. The company has a quick ratio of 2.69, a current ratio of 2.75 and a debt-to-equity ratio of 31.64. Alnylam Pharmaceuticals has a fifty-two week low of $141.98 and a fifty-two week high of $304.39. The business has a 50 day moving average price of $251.82 and a two-hundred day moving average price of $261.70. The firm has a market cap of $35.64 billion, a PE ratio of -105.46 and a beta of 0.35.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.